Intranasal oxytocin as a treatment for obesity: safety and efficacy

References

• Kendrick KM, Guastella AJ, Becker B. Overview of Human Oxytocin Research. Curr Top Behav Neurosci. 2018;35:321–348.
   PubMedGoogle Scholar
• Bhargava R, Daughters KL, Rees A. Oxytocin therapy in hypopituitarism: challenges and opportunities. Clin Endocrinol. 2019;90(2):257–264.
   PubMed Web of Science ®Google Scholar
• Kosfeld M, Heinrichs M, Zak PJ, et al. Oxytocin increases trust in humans. Nature. 2005;435:673–676.
   PubMed Web of Science ®Google Scholar
• Kirsch P, Esslinger C, Chen Q. Oxytocin Modulates Neural Circuitry for Social Cognition and Fear in Humans. J Neurosci. 2005;25(49):11489–11493. DOI:10.1523/JNEUROSCI.3984-05.2005
   PubMed Web of Science ®Google Scholar
• Marsh N, Marsh AA, Lee MR, et al. Oxytocin and the Neurobiology of Prosocial Behavior. Neuroscientist. 2021;27:604–619.
   PubMed Web of Science ®Google Scholar
• Leckman J, Goodman W, North W, et al. The role of central oxytocin in obsessive compulsive disorder and related normal behavior. Psychoneuroendocrinology. 1994;19:723–749.
   PubMed Web of Science ®Google Scholar
• Goh KK, Chen C-H, Lane H-Y. Oxytocin in Schizophrenia: pathophysiology and Implications for Future Treatment. IJMS. 2021;22:2146.
   Google Scholar
• Gottschalk MG, Domschke K. Oxytocin and Anxiety Disorders. In: Hurlemann R Grinevich V, editors. Behavioral Pharmacology of Neuropeptides: oxytocin [Internet]. Cham: Springer International Publishing; 2017[cited 2023 Jan 2]; p. 467–498. Available from: http://link.springer.com/10.1007/7854_2017_25
   Google Scholar
• Giel K, Zipfel S, Hallschmid M. Oxytocin and Eating Disorders: a Narrative Review on Emerging Findings and Perspectives. CN. 2018;16:1111–1121.
   Google Scholar
• Sikich L, Kolevzon A, King BH, et al. Intranasal Oxytocin in Children and Adolescents with Autism Spectrum DisorderIntranasal Oxytocin in Children and Adolescents with Autism Spectrum Disorder. N Engl J Med. 2021;385:1462–1473. DOI:10.1056/NEJMoa2103583
   PubMed Web of Science ®Google Scholar
• Arletti R, Benelli A, Bertolini A. Influence of oxytocin on feeding behavior in the rat. Peptides. 1989;10:89–93.
   PubMed Web of Science ®Google Scholar
• McCormack SE, Blevins JE, Lawson EA. Metabolic Effects of Oxytocin. Endocrine Reviews. 2020;41:121–145.
   PubMed Web of Science ®Google Scholar
• Heisler LK, Lam DD. An appetite for life: brain regulation of hunger and satiety. Curr Opin Pharmacol. 2017;37:100–106.
   PubMed Web of Science ®Google Scholar
• Ye Q, Nunez J, Zhang X. Oxytocin Receptor-Expressing Neurons in the Paraventricular Thalamus Regulate Feeding Motivation through Excitatory Projections to the Nucleus Accumbens Core. J Neurosci. 2022;42:3949–3964.
   PubMed Web of Science ®Google Scholar
• Blevins JE, Graham JL, Morton GJ, et al. Chronic oxytocin administration inhibits food intake, increases energy expenditure, and produces weight loss in fructose-fed obese rhesus monkeys. Am J Physiol Regul Integr Comp Physiol. 2015;308:R431–438.
   PubMed Web of Science ®Google Scholar
• Blevins JE, Thompson BW, Anekonda VT, et al. Chronic CNS oxytocin signaling preferentially induces fat loss in high-fat diet-fed rats by enhancing satiety responses and increasing lipid utilization. Am J Physiol Regul Integr Comp Physiol. 2016;310:R640–658.
   PubMed Web of Science ®Google Scholar
• Maejima Y, Iwasaki Y, Yamahara Y, et al. Peripheral oxytocin treatment ameliorates obesity by reducing food intake and visceral fat mass. Aging. 2011;3:1169–1177.
   PubMedGoogle Scholar
• Deblon N, Veyrat-Durebex C, Bourgoin L, et al. Mechanisms of the anti-obesity effects of oxytocin in diet-induced obese rats. PLoS ONE. 2011;6:e25565.
   PubMed Web of Science ®Google Scholar
• Lawson EA, Marengi DA, DeSanti RL, et al. Oxytocin reduces caloric intake in men: oxytocin Reduces Caloric Intake. Obesity. 2015;23:950–956.
   PubMed Web of Science ®Google Scholar
• Ott V, Finlayson G, Lehnert H, et al. Oxytocin Reduces Reward-Driven Food Intake in Humans. Diabetes. 2013;62:3418–3425.
   PubMed Web of Science ®Google Scholar
• Plessow F, Marengi DA, Perry SK, et al. Effects of Intranasal Oxytocin on the Blood Oxygenation Level-Dependent Signal in Food Motivation and Cognitive Control Pathways in Overweight and Obese Men. Neuropsychopharmacol. 2018;43:638–645.
   PubMed Web of Science ®Google Scholar
• Striepens N, Schröter F, Stoffel-Wagner B, et al. Oxytocin enhances cognitive control of food craving in women: oxytocin and Food Craving. Hum Brain Mapp. 2016;37:4276–4285.
   PubMed Web of Science ®Google Scholar
• Wu C-L, Doong M-L, Wang PS. Involvement of cholecystokinin receptor in the inhibition of gastrointestinal motility by oxytocin in ovariectomized rats. Eur J Pharmacol. 2008;580:407–415.
   PubMed Web of Science ®Google Scholar
• Rinaman L, Rothe EE. GLP-1 receptor signaling contributes to anorexigenic effect of centrally administered oxytocin in rats. Am J Physiol Regul Integr Comp Physiol. 2002;283:R99–106.
   PubMed Web of Science ®Google Scholar
• Lawson EA. The effects of oxytocin on eating behaviour and metabolism in humans. Nat Rev Endocrinol. 2017;13:700–709.
   PubMed Web of Science ®Google Scholar
• van der Klaauw AA, Ziauddeen H, Keogh JM, et al. Oxytocin administration suppresses hypothalamic activation in response to visual food cues. Sci Rep. 2017;7(1):4266. DOI:10.1038/s41598-017-04600-0
   PubMedGoogle Scholar
• Kerem L, Lawson EA. The Effects of Oxytocin on Appetite Regulation, Food Intake and Metabolism in Humans. IJMS. 2021;22:7737.
   Google Scholar
• Maejima Y, Sakuma K, Santoso P, et al. Oxytocinergic circuit from paraventricular and supraoptic nuclei to arcuate POMC neurons in hypothalamus. FEBS Lett. 2014;588:4404–4412.
   PubMed Web of Science ®Google Scholar
• Pischon T, Boeing H, Hoffmann K, et al. General and Abdominal Adiposity and Risk of Death in Europe. N Engl J Med. 2008;359:2105–2120.
   PubMed Web of Science ®Google Scholar
• Altirriba J, Poher A-L, Caillon A, et al. Divergent Effects of Oxytocin Treatment of Obese Diabetic Mice on Adiposity and Diabetes. Endocrinology. 2014;155:4189–4201.
   PubMed Web of Science ®Google Scholar
• Ding C, Leow M‐, Magkos F. Oxytocin in metabolic homeostasis: implications for obesity and diabetes management. Obesity Rev. 2019;20(1):22–40.
   PubMed Web of Science ®Google Scholar
• Kasahara Y, Takayanagi Y, Kawada T, et al. Impaired Thermoregulatory Ability of Oxytocin-Deficient Mice during Cold-Exposure. Biosci Biotechnol Biochem. 2007;71:3122–3126.
   PubMed Web of Science ®Google Scholar
• Takayanagi Y, Kasahara Y, Onaka T, et al. Oxytocin receptor-deficient mice developed late-onset obesity. Neuroreport. 2008;19:951–955.
   PubMed Web of Science ®Google Scholar
• Brede S, Fehr S, Dalla-Man C, et al. Intranasal oxytocin fails to acutely improve glucose metabolism in obese men. Diab Obes Metab. 2019;21(2):424–428. DOI:10.1111/dom.13527
   PubMed Web of Science ®Google Scholar
• Klement J, Ott V, Rapp K, et al. Oxytocin Improves β-Cell Responsivity and Glucose Tolerance in Healthy Men. Diabetes. 2017;66:264–271.
   PubMed Web of Science ®Google Scholar
• Camerino C. Oxytocin Involvement in Body Composition Unveils the True Identity of Oxytocin. IJMS. 2021;22:6383. DOI:10.3390/ijms22126383
   Google Scholar
• Tamma R, Colaianni G, Zhu L, et al. Oxytocin is an anabolic bone hormone. Proc Natl Acad Sci, USA. 2009;106:7149–7154.
   PubMed Web of Science ®Google Scholar
• Plessow F, Marengi DA, Perry SK, et al. Oxytocin Administration Increases Proactive Control in Men with Overweight or Obesity: a Randomized, Double‐Blind, Placebo‐Controlled Crossover Study. Obesity. 2021;29:56–61.
   PubMedGoogle Scholar
• Burmester V, Butler GK, Terry P. Intranasal oxytocin reduces attentional bias to food stimuli. Appetite. 2022;168:105684.
   PubMed Web of Science ®Google Scholar
• Onaka T, Takayanagi Y. Role of oxytocin in the control of stress and food intake. J Neuroendocrinol. 2019;e12700. DOI:10.1111/jne.12700
   PubMed Web of Science ®Google Scholar
• Spetter MS, Feld GB, Thienel M, et al. Oxytocin curbs calorie intake via food-specific increases in the activity of brain areas that process reward and establish cognitive control. Sci Rep. 2018;8:2736.
   PubMed Web of Science ®Google Scholar
• Chen C-Y, Chiang Y-C, Kuo T-C, et al. Effects of intranasal oxytocin in food intake and craving: a meta-analysis of clinical trials. Clin Nutr. 2021;40:5407–5416.
   PubMed Web of Science ®Google Scholar
• van Iersel L, Brokke KE, Adan RAH, et al. Pathophysiology and Individualized Treatment of Hypothalamic Obesity Following Craniopharyngioma and Other Suprasellar Tumors: a Systematic Review. Endocrine Reviews. 2019;40:193–235.
   PubMed Web of Science ®Google Scholar
• Müller HL, Merchant TE, Warmuth-Metz M, et al. Craniopharyngioma. Nat Rev Dis Primers. 2019;5(1):75. DOI:10.1038/s41572-019-0125-9
   PubMed Web of Science ®Google Scholar
• Müller HL. Risk-adapted, long-term management in childhood-onset craniopharyngioma. Pituitary. 2017;20:267–281.
   PubMed Web of Science ®Google Scholar
• Müller HL. Management of Hypothalamic Obesity. Endocrinol Metab Clin North Am. 2020;49:533–552.
   PubMed Web of Science ®Google Scholar
• Roth CL, Aylward E, Liang O, et al. Functional Neuroimaging in Craniopharyngioma: a Useful Tool to Better Understand Hypothalamic Obesity? Obes Facts. 2012;5:243–253.
   PubMed Web of Science ®Google Scholar
• Wang K-W, Chau R, Fleming A, et al. The effectiveness of interventions to treat hypothalamic obesity in survivors of childhood brain tumours: a systematic review. Obes Rev. 2017;18(8):899–914. DOI:10.1111/obr.12534
   PubMed Web of Science ®Google Scholar
• Shah E, Lodh R, Siddell P, et al. Interventions for managing weight change following paediatric acquired brain injury: a systematic review. Dev Med Child Neurol. 2016;58:1004–1008.
   PubMed Web of Science ®Google Scholar
• Bereket A, Kiess W, Lustig RH, et al. Hypothalamic obesity in children. Obes Rev. 2012;13(9):780–798. DOI:10.1111/j.1467-789X.2012.01004.x
   PubMed Web of Science ®Google Scholar
• Haliloglu B, Bereket A. Hypothalamic obesity in children: pathophysiology to clinical management. J Pediatr Endocrinol Metab. 2015;28(5–6):503–513.
   PubMed Web of Science ®Google Scholar
• Daubenbüchel AMM, Hoffmann A, Eveslage M, et al. Oxytocin in survivors of childhood-onset craniopharyngioma. Endocrine. 2016;54:524–531.
   PubMed Web of Science ®Google Scholar
• Hoffmann A, Özyurt J, Lohle K, et al. First experiences with neuropsychological effects of oxytocin administration in childhood-onset craniopharyngioma. Endocrine. 2017;56:175–185.
   PubMed Web of Science ®Google Scholar
• Gebert D, Auer MK, Stieg MR, et al. De-masking oxytocin-deficiency in craniopharyngioma and assessing its link with affective function. Psychoneuroendocrinology. 2018;88:61–69.
   PubMed Web of Science ®Google Scholar
• Brandi M, Gebert D, Kopczak A, et al. Oxytocin release deficit and social cognition in craniopharyngioma patients. J Neuroendocrinol. 2020;32 [[cited 2022 Dec 28]]. InternetAvailable from: https://onlinelibrary.wiley.com/doi/10.1111/jne.12842
   PubMed Web of Science ®Google Scholar
• Özyurt J, Mehren A, Boekhoff S, et al. Social Cognition in Patients with Hypothalamic-Pituitary Tumors. Front Oncol. 2020;10:1014.
   PubMed Web of Science ®Google Scholar
• Daughters K, Manstead ASR, Rees DA. Hypopituitarism is associated with lower oxytocin concentrations and reduced empathic ability. Endocrine. 2017;57(1):166–174.
   PubMed Web of Science ®Google Scholar
• Hsu EA, Miller JL, Perez FA, et al. Oxytocin and Naltrexone Successfully Treat Hypothalamic Obesity in a Boy Post-Craniopharyngioma Resection. J Clin Endocrinol Metab. 2018;103(2):370–375. DOI:10.1210/jc.2017-02080
   PubMed Web of Science ®Google Scholar
• Cook N, Miller J, Hart J. Parent observed neuro-behavioral and pro-social improvements with oxytocin following surgical resection of craniopharyngioma. J Pediatr Endocrinol Metab Internet. [cited 2022 Dec 28] 2016;29(8):995–1000. https://www.degruyter.com/document/doi/10.1515/jpem-2015-0445/html
   PubMed Web of Science ®Google Scholar
• Butler MG, Miller JL, Forster JL. Prader-Willi Syndrome - Clinical Genetics, Diagnosis and Treatment Approaches: an Update. CPR. 2019;15(4):207–244.
   Google Scholar
• Elena G, Bruna C, Benedetta M, et al. Prader-Willi Syndrome: clinical Aspects. J Obes. 2012;2012:1–13.
   Google Scholar
• Gunay-Aygun M, Schwartz S, Heeger S, et al. The Changing Purpose of Prader-Willi Syndrome Clinical Diagnostic Criteria and Proposed Revised Criteria. Pediatrics. 2001;108:e92.
   PubMed Web of Science ®Google Scholar
• Bennett JA, Germani T, Haqq AM, et al. Autism spectrum disorder in Prader-Willi syndrome: a systematic review. Am J Med Genet. 2015;167(12):2936–2944. DOI:10.1002/ajmg.a.37286
   Web of Science ®Google Scholar
• Rosenberg AGW, Wellink CM, Tellez Garcia JM, et al. Health Problems in Adults with Prader–Willi Syndrome of Different Genetic Subtypes: cohort Study, Meta-Analysis and Review of the Literature. JCM. 2022;11:4033.
   Google Scholar
• van Abswoude DH, Pellikaan K, Rosenberg AGW, et al. Bone Health in Adults with Prader–Willi Syndrome: clinical Recommendations Based on a Multicenter Cohort Study. J Clin Endocrinol Metab. 2022;108:59–84.
   PubMed Web of Science ®Google Scholar
• Miller JL, Lynn CH, Driscoll DC, et al. Nutritional phases in Prader-Willi syndrome. Am J Med Genet. 2011;155:1040–1049.
   Web of Science ®Google Scholar
• Muscogiuri G, Barrea L, Faggiano F, et al. Obesity in Prader–Willi syndrome: physiopathological mechanisms, nutritional and pharmacological approaches. J Endocrinol Invest. 2021;44:2057–2070.
   PubMed Web of Science ®Google Scholar
• Fukushima A, Kataoka N, Nakamura K. An oxytocinergic neural pathway that stimulates thermogenic and cardiac sympathetic outflow. Cell Rep. 2022;40:111380.
   PubMed Web of Science ®Google Scholar
• Althammer F, Muscatelli F, Grinevich V, et al. Oxytocin-based therapies for treatment of Prader-Willi and Schaaf-Yang syndromes: evidence, disappointments, and future research strategies. Transl Psychiatry. 2022;12:318.
   PubMed Web of Science ®Google Scholar
• Damen L, Grootjen LN, Juriaans AF, et al. Oxytocin in young children with Prader‐Willi syndrome: results of a randomized, double‐blind, placebo‐controlled, crossover trial investigating 3 months of oxytocin. Clin Endocrinol. 2021;94:774–785.
   PubMed Web of Science ®Google Scholar
• Einfeld SL, Smith E, McGregor IS, et al. A double-blind randomized controlled trial of oxytocin nasal spray in Prader Willi syndrome. Am J Med Genet. 2014;164:2232–2239.
   Web of Science ®Google Scholar
• Hollander E, Levine KG, Ferretti CJ, et al. Intranasal oxytocin versus placebo for hyperphagia and repetitive behaviors in children with Prader-Willi Syndrome: a randomized controlled pilot trial. J Psychiatr Res. 2021;137:643–651.
   PubMed Web of Science ®Google Scholar
• Kuppens RJ, Donze SH, Hokken‐koelega ACS. Promising effects of oxytocin on social and food‐related behaviour in young children with Prader–Willi syndrome: a randomized, double‐blind, controlled crossover trial. Clin Endocrinol. 2016;85:979–987.
   PubMed Web of Science ®Google Scholar
• Miller JL, Tamura R, Butler MG, et al. Oxytocin treatment in children with Prader–Willi syndrome: a double‐blind, placebo‐controlled, crossover study. Am J Med Genet. 2017;173:1243–1250.
   PubMed Web of Science ®Google Scholar
• Tauber M, Boulanouar K, Diene G, et al. The Use of Oxytocin to Improve Feeding and Social Skills in Infants with Prader–Willi Syndrome. Pediatrics. 2017;139:e20162976.
   PubMed Web of Science ®Google Scholar
• Tauber M, Mantoulan C, Copet P, et al. Oxytocin may be useful to increase trust in others and decrease disruptive behaviours in patients with Prader-Willi syndrome: a randomised placebo-controlled trial in 24 patients. Orphanet J Rare Dis. 2011;6:47.
   PubMed Web of Science ®Google Scholar
• WHO. https://www.who.int/news-room/facts-in-pictures/detail/6-facts-on-obesity [Internet]. [cited 2023 Jan 1]. Available from: https://www.who.int/news-room/facts-in-pictures/detail/6-facts-on-obesity.
   Google Scholar
• NCD Risk Factor Collaboration (NCD-RisC). Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19·2 million participants. Lancet. 2016;387:1377–1396.
   PubMed Web of Science ®Google Scholar
• Dai H, Alsalhe TA, Chalghaf N, et al. The global burden of disease attributable to high body mass index in 195 countries and territories, 1990–2017: An analysis of the Global Burden of Disease Study. PLoS Med. 2020;17:e1003198.
   PubMed Web of Science ®Google Scholar
• Bray GA, Heisel WE, Afshin A, et al. The Science of Obesity Management: an Endocrine Society Scientific Statement. Endocrine Reviews. 2018;39:79–132.
   PubMed Web of Science ®Google Scholar
• Zhang H, Wu C, Chen Q, et al. Treatment of obesity and diabetes using oxytocin or analogs in patients and mouse models. PLoS ONE. 2013;8:e61477.
   PubMed Web of Science ®Google Scholar
• Espinoza SE, Lee JL, Wang C-P, et al. Intranasal Oxytocin Improves Lean Muscle Mass and Lowers LDL Cholesterol in Older Adults with Sarcopenic Obesity: a Pilot Randomized Controlled Trial. J Am Med Dir Assoc. 2021;22:1877–1882.e2.
   PubMed Web of Science ®Google Scholar
• MacDonald E, Dadds MR, Brennan JL, et al. A review of safety, side-effects and subjective reactions to intranasal oxytocin in human research. Psychoneuroendocrinology. 2011;36:1114–1126.
   PubMed Web of Science ®Google Scholar
• Quintana DS, Westlye LT, Rustan ØG, et al. Low-dose oxytocin delivered intranasally with Breath Powered device affects social-cognitive behavior: a randomized four-way crossover trial with nasal cavity dimension assessment. Transl Psychiatry. 2015;5:e602.
   PubMed Web of Science ®Google Scholar
• Quintana DS, Westlye LT, Alnæs D, et al. Low dose intranasal oxytocin delivered with Breath Powered device dampens amygdala response to emotional stimuli: a peripheral effect-controlled within-subjects randomized dose-response fMRI trial. Psychoneuroendocrinology. 2016;69:180–188.
   PubMed Web of Science ®Google Scholar
• Quintana DS, Lischke A, Grace S, et al. Advances in the field of intranasal oxytocin research: lessons learned and future directions for clinical research. Mol Psychiatry. 2021;26:80–91.
   PubMed Web of Science ®Google Scholar
• Cai Q, Feng L, Yap KZ. Systematic review and meta-analysis of reported adverse events of long-term intranasal oxytocin treatment for autism spectrum disorder: intranasal oxytocin adverse events. Psychiatry Clin Neurosci. 2018;72:140–151.
   PubMed Web of Science ®Google Scholar
• Buchanan RW, Kelly DL, Strauss GP, et al. Combined Oxytocin and Cognitive Behavioral Social Skills Training for Social Function in People with Schizophrenia. J Clin Psychopharmacol. 2021;41:236–243.
   PubMed Web of Science ®Google Scholar
• Halverson T, Jarskog LF, Pedersen C, et al. Effects of oxytocin on empathy, introspective accuracy, and social symptoms in schizophrenia: a 12-week twice-daily randomized controlled trial. Schizophr Res. 2019;204:178–182.
   PubMed Web of Science ®Google Scholar
• Jarskog LF, Pedersen CA, Johnson JL, et al. A 12-week randomized controlled trial of twice-daily intranasal oxytocin for social cognitive deficits in people with schizophrenia. Schizophr Res. 2017;185:88–95.
   PubMed Web of Science ®Google Scholar
• Modabbernia A, Rezaei F, Salehi B, et al. Intranasal Oxytocin as an Adjunct to Risperidone in Patients with Schizophrenia: an 8-Week, Randomized, Double-Blind, Placebo-Controlled Study. CNS Drugs. 2013;27:57–65.
   PubMed Web of Science ®Google Scholar
• Rung JM, Horta M, Tammi EM, et al. Safety and tolerability of chronic intranasal oxytocin in older men: results from a randomized controlled trial. Psychopharmacology. 2021;238:2405–2418.
   PubMed Web of Science ®Google Scholar